ASX ANNOUNCEMENT **4 August 2025**

CHM CDH17 Clinical Trial Update

- **CHM CDH17 advanced to dose level 2 of 150million CDH17 CAR-T+ cells**
- **Dose level 2 anti-tumour activity seen with no new safety findings to date**
- **Dose level 1 patient remains in stable disease at month 8**

Sydney, Australia, 4 August 2025: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce CHM CDH17 has advanced to Dose Level 2, this follows no safety concerns or off target effects observed at dose level 1.
We're pleased to share encouraging early results from our ongoing clinical trial of CHM CDH17, marking a significant step forward in unlocking the potential of our CAR-T platform.

Dose level 2 has commenced and we have seen one patient with stable disease with anti-tumour activity, shrinking the rapidly growing tumour by approximately 12% at the first scan post the dose of 150million cells. As this is a solid tumour trial, we are mandated to use the RECIST (Response Evaluation Criteria in Solid Tumours) criteria which is a standardized system used to assess how tumours respond to treatment. It provides objective criteria for determining whether a tumour has disappeared, shrunk, stayed the same, or grown. Stable disease is defined as no change in size or up to 30% shrinkage of the imageable tumour. *https://dctd.cancer.gov/research/ctep-trials/for-sites/recist-guidelines-v11.pdf*

Importantly, there has been no evidence of off-target effects or gastrointestinal toxicity and as such the safety window has been passed, we are now cleared to treat more patients at dose level 2.

One patient from the dose level 1 cohort remains with stable disease at month 8 post dose which was 50million cells. Of the imageable tumour we can see a shrinkage by approximately 18% over time. The patient has not had any other treatment throughout this time which provides us more information on the durability of CHM CDH17.

With this safety foundation and signals of anti-tumour activity, we are now continuing dose level 2 to deliver 150million CHM CDH17 CART+ cells in a single dose. "This is great progress, we can see the cells are hard at work; looking forward to more data." Dr Rebecca McQualter, CEO Chimeric Therapeutics.

The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours (NETs). CHM CDH17 is a 3rd generation, novel CAR-T cell therapy that targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumours.

The Phase 1 portion of this study is expected to enrol up to 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies. Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

Contact
Investors
Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au